METABOLON EXPERTS TO LEAD DISCUSSIONS AT INTERNATIONAL METABOLOMICS SOCIETY MEETING
RESEARCH TRIANGLE PARK, NC. (August 18, 2009) — Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, will participate as invited speakers and discussion facilitators at the fifth annual International Conference of the Metabolomics Society. The conference takes place in Edmonton, Alberta, Canada from August 30 to September 2.
John Ryals, Ph.D., Metabolonís chief executive, will address the conference during the Biomedical Biomarkers session with his presentation, titled "The Use of Biochemical Profiling for Biomarker Discovery". He will describe the application of global biochemical profiling for the identification of biomarkers as well as development of diagnostics based on these biomarkers in a variety of disease areas, including cancer.
Metabolonís Chief Scientific Officer, Michael Milburn, Ph.D., will also present during the Biomedical Biomarkers track about the use of metabolomics to distinguish insulin-resistant subjects in a non-diabetic population.
In addition, Metabolonís top metabolomics experts will host six scientific poster sessions at the event offering insight into a variety of research areas. These posters are:
The Metabolomics Society is an organization dedicated to promoting the growth, use and understanding of metabolomics in the life sciences. It is an independent, non-profit organization, governed by a board of directors composed of dedicated members of the metabolomics community. Founded in 2004, the Metabolomics Society now has more than 500 members in more than 20 countries. The Fifth Annual International Conference of the Metabolomics Society brings together attendees from around the world to focus on themes impacting metabolomics. Details about the conference can be viewed online at www.metabolomicssociety.org.
Metabolon is a diagnostics and services company offering the industryís leading biochemical profiling platform. Metabolonís patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.